⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12643605 | 0.76 | GABRP (0.31) | — | |
| SCHEMBL15997770 | 0.73 | HSD17B10 (0.37) | — | |
| SCHEMBL21995903 | 0.72 | HCAR2 (0.51) | — | |
| SCHEMBL1423633 | 0.69 | HDAC1 (0.37) | — | |
| SCHEMBL30687175 | 0.68 | — | — | |
| SCHEMBL15730151 | 0.68 | LMNA (0.31) | — | |
| SCHEMBL4753717 | 0.68 | HCAR2 (0.44) | — | |
| SCHEMBL1006964 | 0.68 | DHODH (0.47) | — | |
| SCHEMBL12643481 | 0.67 | LMNA (0.35) | — | |
| SCHEMBL30850266 | 0.67 | TNKS2 (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230012449-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | GILEAD SCIENCES, INC. | 2023-01-12 | — | — | US | disclosed |
| US-20230012449-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | GILEAD SCIENCES, INC. | 2023-01-12 | — | — | US | disclosed |
| US-11034668-B2 | Compounds for the treatment of HIV | GILEAD SCIENCES, INC. (US) | 2021-06-15 | — | — | US | disclosed |
| US-11034668-B2 | Compounds for the treatment of HIV | GILEAD SCIENCES, INC. (US) | 2021-06-15 | — | — | US | disclosed |
| US-10370358-B2 | Compounds for the treatment of HIV | GILEAD SCIENCES, INC. (US) | 2019-08-06 | — | — | US | disclosed |
| US-10370358-B2 | Compounds for the treatment of HIV | GILEAD SCIENCES, INC. (US) | 2019-08-06 | — | — | US | disclosed |
| US-10202353-B2 | Therapeutic compounds | GILEAD SCIENCES, INC. (US) | 2019-02-12 | — | — | US | disclosed |
| US-10202353-B2 | Therapeutic compounds | GILEAD SCIENCES, INC. (US) | 2019-02-12 | — | — | US | disclosed |
| US-20180194746-A1 | Compounds For the Treatment of HIV | GILEAD SCIENCES, INC. | 2018-07-12 | — | — | US | disclosed |
| US-20180194746-A1 | Compounds For the Treatment of HIV | GILEAD SCIENCES, INC. | 2018-07-12 | — | — | US | disclosed |
| US-9540343-B2 | Compounds for the treatment of HIV | GILEAD SCIENCES, INC. (US) | 2017-01-10 | — | — | US | disclosed |
| US-9540343-B2 | Compounds for the treatment of HIV | GILEAD SCIENCES, INC. (US) | 2017-01-10 | — | — | US | disclosed |
| US-20160368881-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2016-12-22 | — | — | US | disclosed |
| EP-2729448-B1 | COMPOUNDS FOR THE TREATMENT OF HIV | GILEAD SCIENCES INC (US) | 2015-09-09 | — | — | EP | disclosed |
| EP-2729448-B1 | COMPOUNDS FOR THE TREATMENT OF HIV | GILEAD SCIENCES INC (US) | 2015-09-09 | — | — | EP | disclosed |
| US-20140142085-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | GILEAD SCIENCES, INC. (US) | 2014-05-22 | — | — | US | disclosed |
| US-20140142085-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | GILEAD SCIENCES, INC. (US) | 2014-05-22 | — | — | US | disclosed |
| WO-2011077502-A1 | DIHYDROTHIENO[2,3-E]INDAZOLE COMPOUND | 杏林製薬株式会社 (JP) | 2011-06-30 | — | — | WO | disclosed |
| WO-2008148832-A1 | COMPOUNDS WHICH POTENTIATE AMPA RECEPTOR AND USES THEROF IN MEDICINE | GLAXO GROUP LIMITED (GB) | 2008-12-11 | — | — | WO | disclosed |
| WO-2008148832-A1 | COMPOUNDS WHICH POTENTIATE AMPA RECEPTOR AND USES THEROF IN MEDICINE | GLAXO GROUP LIMITED (GB) | 2008-12-11 | — | — | WO | disclosed |